These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 34498507)

  • 1. Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension.
    Pittock SJ; Fujihara K; Palace J; Berthele A; Kim HJ; Oreja-Guevara C; Nakashima I; Levy M; Shang S; Yountz M; Miller L; Armstrong R; Wingerchuk DM;
    Mult Scler; 2022 Mar; 28(3):480-486. PubMed ID: 34498507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension.
    Kim HJ; Nakashima I; Viswanathan S; Wang KC; Shang S; Miller L; Yountz M; Wingerchuk DM; Pittock SJ; Levy M; Berthele A; Totolyan N; Palace J; Barnett MH; Fujihara K;
    Mult Scler Relat Disord; 2021 May; 50():102849. PubMed ID: 33676197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.
    Pittock SJ; Berthele A; Fujihara K; Kim HJ; Levy M; Palace J; Nakashima I; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Fujita KP; Armstrong R; Wingerchuk DM
    N Engl J Med; 2019 Aug; 381(7):614-625. PubMed ID: 31050279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.
    Wingerchuk DM; Fujihara K; Palace J; Berthele A; Levy M; Kim HJ; Nakashima I; Oreja-Guevara C; Wang KC; Miller L; Shang S; Sabatella G; Yountz M; Pittock SJ;
    Ann Neurol; 2021 Jun; 89(6):1088-1098. PubMed ID: 33586143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial.
    Palace J; Wingerchuk DM; Fujihara K; Berthele A; Oreja-Guevara C; Kim HJ; Nakashima I; Levy M; Terzi M; Totolyan N; Viswanathan S; Wang KC; Pace A; Yountz M; Miller L; Armstrong R; Pittock S;
    Mult Scler Relat Disord; 2021 Jan; 47():102641. PubMed ID: 33310418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
    Pittock SJ; Lennon VA; McKeon A; Mandrekar J; Weinshenker BG; Lucchinetti CF; O'Toole O; Wingerchuk DM
    Lancet Neurol; 2013 Jun; 12(6):554-62. PubMed ID: 23623397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
    Cree BAC; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; She D; Rees W; Smith M; Cimbora D; Katz E; Bennett JL;
    Lancet Neurol; 2024 Jun; 23(6):588-602. PubMed ID: 38760098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
    Marignier R; Pittock SJ; Paul F; Kim HJ; Bennett JL; Weinshenker BG; Wingerchuk DM; Green AJ; Fujihara K; Cutter G; Aktas O; Hartung HP; Drappa J; Ratchford JN; She D; Smith M; Rees W; Cimbora D; Katz E; Cree BAC;
    Mult Scler Relat Disord; 2022 Jan; 57():103356. PubMed ID: 35158465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
    Frampton JE
    Drugs; 2020 May; 80(7):719-727. PubMed ID: 32266705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
    Carnero Contentti E; Correale J
    J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
    Yamamura T; Kleiter I; Fujihara K; Palace J; Greenberg B; Zakrzewska-Pniewska B; Patti F; Tsai CP; Saiz A; Yamazaki H; Kawata Y; Wright P; De Seze J
    N Engl J Med; 2019 Nov; 381(22):2114-2124. PubMed ID: 31774956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
    Nie T; Blair HA
    CNS Drugs; 2022 Oct; 36(10):1133-1141. PubMed ID: 36070074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD): fatal outcome.
    Doubrovinskaja S; Korporal-Kuhnke M; Jarius S; Haas J; Wildemann B
    J Neurol; 2024 May; 271(5):2866-2870. PubMed ID: 37962590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
    Traboulsee A; Greenberg BM; Bennett JL; Szczechowski L; Fox E; Shkrobot S; Yamamura T; Terada Y; Kawata Y; Wright P; Gianella-Borradori A; Garren H; Weinshenker BG
    Lancet Neurol; 2020 May; 19(5):402-412. PubMed ID: 32333898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial on: Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
    Pardo S; Giovannoni G; Hawkes C; Lechner-Scott J; Waubant E; Levy M
    Mult Scler Relat Disord; 2019 Aug; 33():A1-A2. PubMed ID: 31324299
    [No Abstract]   [Full Text] [Related]  

  • 16. Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
    Fung S; Shirley M
    CNS Drugs; 2023 Apr; 37(4):363-370. PubMed ID: 36933107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatment.
    Sen S; Tuncer A; Terzi M; Bunul SD; Ozen-Acar P; Altunrende B; Ozakbas S; Tutuncu M; Uygunoglu U; Akman-Demir G; Karabudak R; Efendi H; Siva A
    Mult Scler Relat Disord; 2023 Nov; 79():104949. PubMed ID: 37678131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar.
    Kleiter I; Traboulsee A; Palace J; Yamamura T; Fujihara K; Saiz A; Javed A; Mayes D; Büdingen HV; Klingelschmitt G; Stokmaier D; Bennett JL
    Neurol Neuroimmunol Neuroinflamm; 2023 Jan; 10(1):. PubMed ID: 36724181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the treatment of neuromyelitis optica spectrum disorders.
    Romeo AR
    Curr Opin Rheumatol; 2021 May; 33(3):233-239. PubMed ID: 33741809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.
    Zhang C; Zhang M; Qiu W; Ma H; Zhang X; Zhu Z; Yang CS; Jia D; Zhang TX; Yuan M; Feng Y; Yang L; Lu W; Yu C; Bennett JL; Shi FD;
    Lancet Neurol; 2020 May; 19(5):391-401. PubMed ID: 32333897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.